ERN-LUNG

ERN-LUNG is a service oriented network for patients and healthcare providers in rare respiratory diseases across Europe and wants to be the one-stop information hub. 

Our vision is to transfer knowledge and develop expertise through education and training, rather than making patients or experts travel. 

We want to support and train a new generation of highly skilled care teams for rare diseases oft e respiratory system in all Member States .

ERN-LUNG, in cooperation with ERS, has made available useful info and learning material (e.g. webinars, publications) for you.

Enjoy the content!

Educational resources


ILD CF PH

Congress sessions

  • State of the art session, Interstitial lung diseases, ERS virtual congress 2020
Chronic Hypersensitivity pneumonitis: risks factors and therapeutic options
A. Wells (London, United Kingdom)
WebcastSlide presentation
WebcastSlide presentation
Genetics in ILDs: what does the future hold?
M. Molina Molina (Barcelona, Spain)
WebcastSlide presentation
WebcastSlide presentation
Invasive approaches in the diagnosis of ILDs
C. Ravaglia (Forlì, Italy)
WebcastSlide presentation
WebcastSlide presentation
How systemic inflammatory diseases affect the lung
M. Kreuter (Heidelberg, Germany)
WebcastSlide presentation
WebcastSlide presentation
  • Symposium, Severe thoracic sarcoidosis : where do we stand ?, ERS virtual congress 2020
Pathogenesis of pulmonary fibrosis in sarcoidosis
J. Grutters (Nieuwegein, Netherlands)
WebcastSlide presentation
WebcastSlide presentation
Genetic and non-genetic risk factors for severe pulmonary sarcoidosis
P. Spagnolo (Padova (PD), Italy)
WebcastSlide presentation
WebcastSlide presentation
Severe pulmonary sarcoidosis: definition and risk stratification
D. Culver (Cleveland, United States of America)
WebcastSlide presentation
WebcastSlide presentation
Management of cardiac sarcoidosis
V. Kouranos (London, United Kingdom)
WebcastSlide presentation
WebcastSlide presentation

Webinars

COVID-19: Current Challenges in ILD
C. Robalo Cordeiro (Coimbra, Portugal), M. Molina Molina (Barcelona, Spain), M. Wijsenbeek (Rotterdam, Netherlands)

Tuesday, 21 December 2020
WebcastSlide presentation
WebcastSlide presentation
COVID-19 and the management of Interstitial Lung Diseases patients: challenges and recommendations
Venerino Poletti (Forli, Italy), Katerina Antoniou (Heraklion, Greece), Elizabeth Renzoni (London, United Kingdom), Sara Tomassetti (Forli, Italy), Athol Wells (London, United Kingdom), Sergio Harari (Milan, Italy), Giorgina Dalpiaz (Bologna, Italy), Bruno Crestani (Paris, France)

Thursday, 4 June 2020
Slide presentationWebcast
Slide presentationWebcast
COVID-19 in patients with rare diseases of the respiratory system
DG Sante (European commission), T.O. F. Wagner (Frankfurt/Main, Germany), I. Fajac (Paris, France), M. Kreuter (Heidelberg, Germany), G. Verleden (Leuven, Belgium), M. Humbert (Paris, France), Heymut Omran (Münster, Germany)

Thursday, 30 April 2020
WebcastPDF journal article, handout or slides
WebcastPDF journal article, handout or slides

Interactive e-learning content

Webcasts

COVID-19: Current Challenges in ILD
C. Robalo Cordeiro (Coimbra, Portugal), M. Molina Molina (Barcelona, Spain), M. Wijsenbeek (Rotterdam, Netherlands)

Tuesday, 21 December 2020
WebcastSlide presentation
WebcastSlide presentation
Management of ILD patients in ICU
M. Kokosi (London, United Kingdom)
WebcastSlide presentation
WebcastSlide presentation
Selection of ILD patients for ICU and ECMO
C. Agerstrand (New York, United States of America)
WebcastSlide presentation
WebcastSlide presentation
Pro-con debate: Does it make sense to view rapidly progressive ILD as a distinct clinical entity? - PRO
E. Renzoni (London, United Kingdom)
WebcastSlide presentation
WebcastSlide presentation
Pro-con debate: Does it make sense to view rapidly progressive ILD as a distinct clinical entity? - CON
V. Cottin (Lyon, France)
WebcastSlide presentation
WebcastSlide presentation
Benefits of high-flow nasal cannula oxygen therapy on exercise capacity following acute exacerbation in ILD patients
S. Arizono (Hamamatsu (Shizuoka), Japan), M. Oomagari (Hamamatsu (Shizuoka), Japan), Y. Yanagita (Hamamatsu (Shizuoka), Japan), H. Machiguchi (Hamamatsu (Shizuoka), Japan), Y. Tawara (Hamamatsu (Shizuoka), Japan), K. Yokomura (Hamamatsu (Shizuoka), Japan)
Congress or journal article abstractWebcastSlide presentationE-poster
Congress or journal article abstractWebcastSlide presentationE-poster
Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial
K. Flaherty (Ann Arbor, MI, United States of America), A. Wells (London, United Kingdom), V. Cottin (Lyon, France), A. Devaraj (London, United Kingdom), Y. Inoue (Sakai City, Osaka, Japan), L. Richeldi (Rome, Italy), S. Walsh (London, United Kingdom), M. Kolb (Hamilton, Ontario, Canada), D. Koschel (Coswig, Germany), T. Moua (Rochester, MN, United States of America), S. Stowasser (Ingelheim am Rhein, Germany), R. Goeldner (Biberach, Germany), R. Schlenker-Herceg (Ridgefield, CT, United States of America), K. Brown (Denver, CO, United States of America)
Congress or journal article abstractWebcastSlide presentationE-poster
Congress or journal article abstractWebcastSlide presentationE-poster
Does histology matter in ILD-CTD?
V. Poletti (Forlì, Italy)
WebcastSlide presentation
WebcastSlide presentation
Interstitial lung disease (ILD) and multicompartment assessment of CTD: where should the respiratory physician begin?
C. Denton (London, United Kingdom)
WebcastSlide presentation
WebcastSlide presentation
To be or not to be – the uncertainty of PF-ILD
M. Kreuter (Heidelberg, Germany), N. Kahn (Heidelberg, Germany), F. Sambataro (Heidelberg, Germany), C. Heussel (Heidelberg, Germany), G. Sambataro (Catania, Italy), C. Vancheri (Catania, Italy), S. Torrisi (Heidelberg, Germany)
Congress or journal article abstractWebcastSlide presentationE-poster
Congress or journal article abstractWebcastSlide presentationE-poster
ILD
S. Harari (Milano (MI), Italy)
WebcastSlide presentation
WebcastSlide presentation
Lung ultrasound in children with interstitial lung disease: a pilot study.
C. Delestrain (Creteil, France), G. Thouvenin (Creteil, France), N. Richard (Creteil, France), F. Madhi (Creteil, France), L. Berdah (Creteil, France), H. El Jurdi (Creteil, France), A. Clement (Creteil, France), R. Epaud (Creteil, France), H. Corvol (Creteil, France), N. Nathan (Creteil, France)
Congress or journal article abstractWebcastSlide presentationE-poster
Congress or journal article abstractWebcastSlide presentationE-poster
Assessment of fibrosis in lung biopsies from the European childhood interstitial lung disease (chILD) registry
M. Griese (Munich, Germany), E. Seidl (Munich, Germany), K. Knoflach (Munich, Germany), J. Ley-Zaporozhan (Munich, Germany), B. Kammer (Munich, Germany), I. Krueger-Stollfuss (Munich, Germany), S. Reu-Hofer (Wuerzburg, Germany), N. Schwerk (Hannover, Germany), J. Carlens (Hannover, Germany), M. Wetzke (Hannover, Germany), N. Emiralioglu (Ankara, Turkey), N. Kiper (Ankara, Turkey), F. Stehling (Essen, Germany), J. Lange (Warsaw, Poland), K. Krenke (Warsaw, Poland)
Congress or journal article abstractWebcastSlide presentationE-poster
Congress or journal article abstractWebcastSlide presentationE-poster
Management of ILD patients in ICU
M. Kokosi (London, United Kingdom)
WebcastSlide presentation
WebcastSlide presentation
Diagnostic procedures in ICU: bronchoscopy and BAL or tissue?
C. Ravaglia (Forlì, Italy)
WebcastSlide presentation
WebcastSlide presentation
Radiological patterns in ICU: does it matter?
N. Sverzellati (Parma (PR), Italy)
WebcastSlide presentation
WebcastSlide presentation
Selection of ILD patients for ICU and ECMO
C. Agerstrand (New York, United States of America)
WebcastSlide presentation
WebcastSlide presentation
The role of cell lines in modelling the type II pneumocyte in interstitial lung disease
J. Dickens (Cambridge (Cambridgeshire), United Kingdom)
WebcastSlide presentation
WebcastSlide presentation
Lung-on-a -chip: state of the art
N. Roldan (Bern, Switzerland)
WebcastSlide presentation
WebcastSlide presentation
Using induced pluripotent stem cells to study the type II pneumocyte
K. Hurley (Dublin 3, Ireland)
WebcastSlide presentation
WebcastSlide presentation
3D tissue culture to study the mechanisms of lung repair in IPF
M. Konigshoff (Denver, United States of America)
WebcastSlide presentation
WebcastSlide presentation
Microbiome effects on immunity, health and diseases of the lungs
K. Antoniou (Heraklion, Greece)
WebcastSlide presentation
WebcastSlide presentation
Intrinsic and extrinsic environmental factors in IPF
G. Raghu (Seattle, United States of America)
WebcastSlide presentation
WebcastSlide presentation
Interstitial lung disease and air pollution: in India and beyond
S. Singh (Jaipur (Rajasthan), India)
WebcastSlide presentation
WebcastSlide presentation
Air pollution: particle size matters
H. Davies (Vancouver, Canada)
WebcastSlide presentation
WebcastSlide presentation
Genetic predisposition and the environment
M. Molina Molina (Barcelona, Spain)
WebcastSlide presentation
WebcastSlide presentation
Combined assessment of regional lung function and morphology using a contrast enhanced Dual-Energy CT protocol: Prospective value of functional imaging biomarkers in longitudinal analysis of patients with Interstitial Lung Disease
S. Scharm (Hannover, Germany), S. Dettmer (Hannover, Germany), J. Vogel-Claussen (Hannover, Germany), A. Prasse (Hannover, Germany), L. Knudsen (Hannover, Germany), F. Wacker (Hannover, Germany), J. Fuge (Hannover, Germany), H. Shin (Hannover, Germany)
Congress or journal article abstractWebcastSlide presentationE-poster
Congress or journal article abstractWebcastSlide presentationE-poster
Methotrexate and risk of Lung disease in Rheumatoid Arthritis: A nationwide population-based cohort study from Denmark
S. Burhan Shaker (Copenhagen, Denmark), E. Ibfelt (Copenhagen, Denmark), R. Jacobsen (Copenhagen, Denmark), T. Kopp (Copenhagen, Denmark), R. Cordtz (Aalborg, Denmark), A. Jakobsen (Copenhagen, Denmark), N. Seersholm (Copenhagen, Denmark), L. Dreyer (Aalborg, Denmark)
Congress or journal article abstractWebcastSlide presentationE-poster
Congress or journal article abstractWebcastSlide presentationE-poster
Beyond the lungs in fibrotic interstitial lung disease: does supplemental O2 improve skeletal muscle oxygenation and fatigue?
M. Marillier (Kingston, Canada), A. Bernard (Kingston, Canada), O. Moran-Mendoza (Kingston, Canada), D. O'Donnell (Kingston, Canada), S. Verges (Grenoble, France), J. Neder (Kingston, Canada)
Congress or journal article abstractWebcastSlide presentationE-poster
Congress or journal article abstractWebcastSlide presentationE-poster
Oxygen enhanced MRI biomarkers of lung function in interstitial lung disease
M. Tibiletti (Manchester, United Kingdom), J. Naish (Manchester, United Kingdom), M. Heaton (Manchester, United Kingdom), J. Waterton (Manchester, United Kingdom), P. Hughes (Sheffield, United Kingdom), J. Eaden (Sheffield, United Kingdom), S. Skeoch (Bath, United Kingdom), N. Chaudhuri (Manchester, United Kingdom), I. Bruce (Manchester, United Kingdom), S. Bianchi (Sheffield, United Kingdom), J. Wild (Sheffield, United Kingdom), G. Parker (Manchester, United Kingdom)
Congress or journal article abstractWebcastSlide presentationE-poster
Congress or journal article abstractWebcastSlide presentationE-poster
B-cell suppressive therapy and monoclonal antibodies in CTD: does one size fit all?
D. Kyburz (Basel, Switzerland)
WebcastSlide presentation
WebcastSlide presentation
Fibrotic CTD and interstitial pneumonia with autoimmune features (IPAF): immunosuppressive or/and anti-fibrotic treatment?
S. Danoff (Baltimore, United States of America)
WebcastSlide presentation
WebcastSlide presentation
Does histology matter in ILD-CTD?
V. Poletti (Forlì, Italy)
WebcastSlide presentation
WebcastSlide presentation
Interstitial lung disease (ILD) and multicompartment assessment of CTD: where should the respiratory physician begin?
C. Denton (London, United Kingdom)
WebcastSlide presentation
WebcastSlide presentation
Why should we care for the vessels in interstitial lung disease?
H. Olschewski (Graz, Austria)
WebcastSlide presentation
WebcastSlide presentation
Pleural effusion in Niemann Pick Disease - associated Interstitial Lung Disease
E. Boynton (Cambridge, United Kingdom)
WebcastSlide presentation
WebcastSlide presentation
Granulomatous lung disease in lymphoma patient after rituximab treatment
P. Janowiak (Gdansk, Poland)
WebcastSlide presentation
WebcastSlide presentation
Mechanical ventilation in interstitial lung disease
M. Dres (Paris, France)
PDF journal article, handout or slidesWebcast
PDF journal article, handout or slidesWebcast